HARBIN, China, Aug. 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the launch of its new corporate website under the domain name http://www.cski.com.cn .
The new website features an expanded overview of the Company, including its corporate structure, sales network, R&D efforts, as well as a detailed introduction to its product portfolio. The new website also includes a richer section dedicated to investor relations, in keeping with its increased profile in the investor community as a U.S. publicly traded company on the NASDAQ Global Market.
"We are pleased to officially launch our new corporate website, which serves as a resource for customers, investors, and business partners to efficiently access information on our Company," said Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "Through frequent and regular updates, we believe our website will become an effective tool to increase awareness of our business and our products within the investment community."
"We welcome direct communications with our shareholders, and look forward to answering any questions that they may have," said Mr. Stanley Hao, CFO of China Sky One Medical. "Should you have any questions about our business and financial statements, please contact us through our outside investor relations firm, CCG Investor Relations, or via email at stanleyhao@cski.com.cn.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the launch of new website. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-451-5399-4069
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
